e-learning
resources
Paris 2018
Sunday, 16.09.2018
Risk stratification in treatment of pulmonary arterial hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Early improvements predict outcomes in pulmonary arterial hypertension
R. White (Rochester Medical Center, United States of America), C. Vizza (Rome, Italy), C. Blair (Foster City, United States of America), J. Langley (Brentford, United Kingdom), M. Hoeper (Hannover, Germany)
Source:
International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Session:
Risk stratification in treatment of pulmonary arterial hypertension
Session type:
Oral Presentation
Number:
269
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. White (Rochester Medical Center, United States of America), C. Vizza (Rome, Italy), C. Blair (Foster City, United States of America), J. Langley (Brentford, United Kingdom), M. Hoeper (Hannover, Germany). Early improvements predict outcomes in pulmonary arterial hypertension. 269
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Early detection and management of pulmonary arterial hypertension
Source: Eur Respir Rev 2012 21: 306-312
Year: 2012
Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension
Source: Eur Respir J 2011; 38: 608-616
Year: 2011
Improving survival in pulmonary arterial hypertension
Source: Eur Respir J 2005; 25: 218-220
Year: 2005
Pregnancy outcomes in pulmonary arterial hypertension in the modern management era
Source: Eur Respir J 2012; 40: 1304-1305
Year: 2012
Improving patient outcomes in pulmonary hypertension
Source: Eur Respir Rev 2015; 24: 550-551
Year: 2015
Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Em
PH
asis-10 is associated with clinical outcome measures in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Interpreting risk reduction in clinical trials for pulmonary arterial hypertension
Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018
Year: 2018
Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
Source: Eur Respir J, 50 (4) 1700465; 10.1183/13993003.00465-2017
Year: 2017
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Source: Eur Respir J, 51 (5) 1800629; 10.1183/13993003.00629-2018
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018
The future of treatment for pulmonary arterial hypertension
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014
The future of treatment for pulmonary arterial hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012
The future of treatment for pulmonary arterial hypertension
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Renal dysfunction correlates with impaired hemodynamics and unfavorable outcome in pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects
Year: 2010
Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension
Source: Eur Respir J 2012; 39: 939-944
Year: 2012
Identification of treatment goals in paediatric pulmonary arterial hypertension
Source: Eur Respir J 2014; 44: 1616-1626
Year: 2014
Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure
Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept